Post-marketing safety of pimavanserin: a real-world pharmacovigilance study based on the FDA adverse event reporting system (FAERS)
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性,不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1080/14740338.2025.2460444
文献链接: https://www.tandfonline.com/doi/full/10.1080/14740338.2025.2460444
其他信息:
出版社: Informa UK Limited
作者: Dong Liu; Xueni Zhang; Haiyan Xu
全文下载地址: https://www.tandfonline.com/doi/pdf/10.1080/14740338.2025.2460444

